Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217

Fig. 3

Differences in plasma p-tau217 according to diagnostic groups. The groups in cohort 2 were stratified according to amyloid status (Aβ+ = CSF Aβ42/Aβ40 ratio < 0.07) and clinical diagnosis at follow-up (e.g., MCI-AD Aβ+ has AD dementia at follow-up). Brackets indicate significant differences between the groups, determined by general linear models with post hoc LSD tests, adjusted for age, sex, and [in cohort 2] total follow-up time. The y-axes represent the z-scored plasma p-tau217 levels in order to facilitate an easier visual comparison between the two assays. AUC, area under the curve

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193